
Nyxoah presented 12-month ACCCESS data, showing a 77.2% responder rate for its Genio implant in sleep apnea patients with complete concentric collapse. The company also filed with the FDA to expand its US label. Days later, it lowered its 2026 revenue guidance to €33M-€35M, citing a slower-than-expected US rollout.
Nyxoah reported that its ACCCESS pivotal study met its primary safety and efficacy endpoints in patients with complete concentric collapse, a form of obstructive sleep apnea excluded from competing nerve-stimulation therapies. Across 47 patients, Genio achieved a 77.2% responder rate on the apnea-hypopnea index, with no device-related serious adverse events. The leadless, battery-free implant stimulates both sides of the hypoglossal nerve to keep the airway open during sleep. Nyxoah is preparing an FDA submission to expand Genio's US indication and has separately begun its BREATHE post-approval study.